CHRONIC GRAFT VS. HOST DISEASE
Clinical trials for CHRONIC GRAFT VS. HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT VS. HOST DISEASE trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT VS. HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may help lung damage after stem cell transplants
Disease control OngoingThis study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…
Matched conditions: CHRONIC GRAFT VS. HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental drug axatilimab made available for one patient with chronic GVHD
Disease control APPROVED_FOR_MARKETINGThis program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics commi…
Matched conditions: CHRONIC GRAFT VS. HOST DISEASE
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC